Steris PLC (NYSE:STE) Director Mohsen Sohi sold 3,121 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $165.65, for a total transaction of $516,993.65. Following the completion of the sale, the director now directly owns 25,482 shares of the company’s stock, valued at $4,221,093.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
NYSE:STE opened at $168.51 on Friday. The company has a 50-day moving average price of $153.20 and a 200-day moving average price of $149.19. Steris PLC has a 12 month low of $118.18 and a 12 month high of $168.61. The company has a current ratio of 2.41, a quick ratio of 1.86 and a debt-to-equity ratio of 0.73. The stock has a market cap of $14.29 billion, a price-to-earnings ratio of 36.63 and a beta of 0.90.
Steris (NYSE:STE) last issued its quarterly earnings results on Monday, February 10th. The medical equipment provider reported $1.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.42 by $0.03. The company had revenue of $774.30 million during the quarter, compared to analyst estimates of $748.45 million. Steris had a net margin of 13.21% and a return on equity of 17.32%. Steris’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same period last year, the business earned $1.26 EPS. Equities analysts forecast that Steris PLC will post 5.58 EPS for the current fiscal year.
Several research firms have recently commented on STE. Northcoast Research reaffirmed a “buy” rating on shares of Steris in a research report on Wednesday. Stephens raised their target price on shares of Steris from $165.00 to $177.00 and gave the stock an “overweight” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $152.75.
Several institutional investors have recently modified their holdings of STE. Pictet Asset Management Ltd. bought a new position in shares of Steris in the 4th quarter worth about $131,374,000. State Street Corp increased its stake in Steris by 27.5% during the 4th quarter. State Street Corp now owns 3,587,820 shares of the medical equipment provider’s stock valued at $546,856,000 after purchasing an additional 774,516 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Steris by 132.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,053,593 shares of the medical equipment provider’s stock valued at $160,588,000 after purchasing an additional 600,507 shares in the last quarter. BlackRock Inc. increased its stake in Steris by 6.1% during the 2nd quarter. BlackRock Inc. now owns 9,052,709 shares of the medical equipment provider’s stock valued at $1,347,769,000 after purchasing an additional 522,254 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Steris by 14.6% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,950,497 shares of the medical equipment provider’s stock valued at $297,294,000 after purchasing an additional 248,912 shares in the last quarter. Institutional investors own 86.78% of the company’s stock.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Recommended Story: Why are percentage gainers important?
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.